-
Featured Authors
-
Archives
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: FDA
Driving Innovation through Federal Investments
Today, BIO submitted testimony to the Senate Committee on Appropriations on the importance of driving innovation through federal investments. Below are highlights of our written testimony. NIH: A Driver of the Innovation Pipeline We must continue to invest in scientific discovery. NIH-supported biomedical research builds the foundation of scientific and clinical knowledge that is widely communicated and used to improve the treatment of patients and underpin the development of new diagnostics, treatments, vaccines, and cures. Read More >
BIO Calls on Appropriators to Fully Fund FDA
BIO issued letters today encouraging support for programs and initiatives of critical importance to our industry as appropriators develop the Fiscal Year 2015 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act. Perhaps most importantly, we emphasize the importance of a strong, fully-funded FDA with the resources necessary to keep pace with rapidly-evolving biomedical science and to make sound regulatory decisions in a timely and efficient manner. We are requesting a total Read More >
“No Need to Label GMOs” Says FDA
The Nation’s Leading Regulatory Body on Food Safety Reaffirms Safety of GMOs On March 28, 2014, the Food and Drug Administration Commissioner Margaret Hamburg testified to the House Appropriations Committee on the FDA’s 2015 budget request. In a line of questioning, she was asked about the labeling of GMOs. The Hill’s Benjamin Goad tracked her response reaffirming that the FDA will not label GM foods. “Margaret Hamburg told lawmakers this week that the agency remains Read More >
FDA: Vaccines a Critical Tool in Protecting and Promoting Public Health
Yesterday, Dr. Karen Midthun of the FDA wrote about the important role of vaccines in promoting public health: Vaccines are a critical tool in protecting and promoting the public health in the U.S. and around the world. The risks from childhood diseases like measles, mumps and polio have been greatly reduced, or in the case of polio, eliminated in the U.S. Vaccines are one of the great public health success stories of the 20th century. Dr. Midlun Read More >
U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14
During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, co- chair of the Congressional Biomedical Research Caucus, joined BIO’s Fritz Bittenbender to discuss the biotech industry in Pennsylvania as well as recent legislative developments affecting the industry. Dent points to the recent omnibus spending agreement which allowed the Food and Drug Administration (FDA) to access user $85 million in user fees sequestered in 2013. These fees are paid to Read More >
